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Abstract 
Objectives: Restless legs syndrome (RLS) symptoms are common in Multiple 
Sclerosis (MS) patients. The aim of the current study was to examine for the first time 
whether RLS could affect the functional capacity and various contributors parameters 
related to quality of life and fatigue in MS patients.   
Methods: According to their RLS status, fifty relapsing-remitting MS patients were 
divided into the RLS (n= 10) and non-RLS group (n= 40). Specific questionnaires 
were used in order to assess the health-related quality of life (HRQoL), fatigue levels, 
sleep quality, daily sleepiness and depression symptoms of the patients. Functional 
capacity was examined using a battery of functional tests. Total body and visceral fat 
levels were assessed via bioelectrical impedance analyzers.   
Results: Sleep quality, depression, fatigue and HRQoL levels were found to be 
significantly worse in the patients with RLS compared to their free-RLS counterparts 
(p <0.05). In addition, the patients with RLS were found to exhibit further 
impairments in their performance in various functional tests related mainly with 
strength levels of lower extremities (p <0.05). Finally, the patients with RLS were 
found to have significantly higher both total and trunk fat levels compared to the 
patients without RLS (p <0.05). A strong correlation was observed between the 
severity of RLS symptoms, sleep quality, fatigue and QoL levels.  
Discussion: It seems that RLS contributes even further to impairments on sleep 
quality, fatigue, functional capacity and therefore HRQoL levels in relapsing-
remitting MS patients, whilst for first time a link between high fat levels has been 
revealed also.  
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Introduction 
Restless legs syndrome (RLS)/Willis-Ekbom disease is a common neurologic disorder 
characterized by an irresistible need to move the legs, usually accompanied by 
unpleasant sensations [1], which begins or worsen during inactivity, especially in the 
evening/night, and improves or disappear by movement [1]. Even though the 
mechanism behind RLS is unclear, available data suggest a possible dysfunction of 
dopaminergic, opioid and iron metabolism in the central nervous system [2]. 
Recently, another interesting theory advocates peripheral hypoxia [3] as an interesting 
peripheral trigger of RLS symptoms. RLS is more common and more severe in 
Multiple Sclerosis (MS) [4, 5] than in general population, with a prevalence rate 
ranging between 13.3% to 65.1% [6]. 
  
Sleep disorders merit further attention in patients with MS given the potential impact 
on overall health and health-related quality of life (HRQoL) [7]. Moreover, sleep 
disorders can contribute to depression and fatigue, symptoms that are extremely 
frequent in MS patients[7], resulting to impaired HRQoL [8]. Indeed, evidences 
revealed that the MS patients with RLS exhibit poorer subjective sleep quality and 
greater disability and fatigue levels compared to their free-RLS counterparts[9]. It is 
still unknown whether RLS can affect the functional capacity and body composition 
of the MS patients, fact that could significantly contribute to even further impairments 
on HRQoL, fatigue and mental health of the current population.  
 
The aim of the current study was to examine for the first time whether RLS could 
affect the functional capacity and various contributors parameters related to quality of 
life and fatigue in relapsing-remitting MS patients.  The null hypothesis is that the MS 
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patients suffering also from RLS have the same level of health-related quality of life, 
functional capacity and fatigue compared to the MS patients without RLS.  
 
 
Methods 
Participants 
Fifty patients with relapsing-remitting MS were agreed to participate in this study. 
MS was diagnosed according to the revised McDonald criteria (2005), whilst the 
patients’ disability level was assessed by the expanded disability status scale (EDSS) 
[10]. The examination was performed always during a period of disease remission, at 
least 3 months after the last clinical relapse. The patients need to have an Expanded 
Disability Status Scale (EDSS) score between 0 and 5.5 and an age of 18-65 years. 
The patients were consecutively recruited from the neurology clinics of the Cyprus 
Institute of Neurology and Genetics, Nicosia, Cyprus. According to their RLS status, 
the patients were divided into two groups: the RLS group (n= 10, MS-RLS+) and the 
non-RLS group (n=40, MS-RLS-). RLS was diagnosed by a face to face interview 
conducted by a neurologist expert in RLS  by using the updated diagnostic criteria 
from the International RLS Study Group (IRLSSG) [1], whilst the severity of the RLS 
symptoms was evaluated using the IRLSSG severity rating scale (IRLS) [11]. All of 
the patients receive the diagnosis of MS within 2 years before of the RLS assessment. 
Inclusion criteria were that patients experienced the RLS symptoms at least three 
times per week, MRI showing lesions consistent with MS and at least one documented 
clinical relapse. Patients excluded from the study if they have been diagnosed with 
other neurological diseases (other than MS), have any signs or symptoms of 
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secondary RLS (eg, RLS secondary to chronic renal failure, pregnancy, iron 
deficiency and anaemia) or any recent clinical relapse (within 3 months prior to the 
initialization of the study). All patients gave their written consent. The study 
conformed to the principles enumerated in the Helsinki Declaration and was approved 
by the local Ethics Committee (national). 
 
Anthropometry and body composition assessment 
The patients’ height was measured using a standing stadiometer (Seca model 720, 
Germany). Body weight was recorded to the nearest 0.05 kg using an analogue scale 
(Seca model 755, Germany). Body mass index (BMI) was calculated as body weight 
divided by height squared. Total body fat and trunk fat were both assessed by 
bioelectrical impedance analyzers (Bodystat, Quadscan 4000 and Tanita AB 140 
Viscan respectively). The later analyzer provided also abdominal girth data of the 
patients in cm.  
 
Questionnaires 
Health-related quality of life levels were evaluated using the SF-36 questionnaire 
[12]. The patients’ depressive symptoms were assessed by using the Beck Depression 
Inventory (BDI) [13]. Subjective sleep quality was assessed by using the Pittsburg 
sleep quality index (PSQI) [14]. Fatigue levels were assessed by using the fatigue 
severity scale  (FSS) [15]. Finally, the patients’ daily sleepiness status was assessed 
by using the Epworth sleepiness scale (ESS) [16]. We should note that all 
questionnaires were completed using the interview method. 
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Functional capacity assessment 
The patients’ functional capacity was assessed by a battery of tests. In particular, the 
patients performed two Sit-to-Stand tests (STS-5 and STS-60) [17] the six minute 
walk test [18] and the timed up and go test (TUG) [19]. The STS-5 requires from the 
patient to perform five sit-to-stand cycles as fast as possible measured in seconds, and 
can be used as an indicator of the patient’s lower extremities strength.  The STS-60 is 
a similar test that requires from the patient to stand up and sit down to a chair as many 
times as possible in 60 seconds. The score is the total number of sit to stands cycles 
within 60 seconds (the number achieved in 30 seconds was recorded also) and it is an 
index of muscular endurance. The six minute walk test requires from the patient to 
cover as much ground is possible in six minutes (the covered distance was recorded in 
meters). The TUG test requires from the patient to rise from a chair, walk to a line on 
the floor three meters away, turn and walk back to the chair and sit down again. A 
faster time indicates a better functional performance.  
 
Biochemical Assessment 
The biochemical examination of blood samples including haemoglobin, hematocrit, 
iron, and ferritin was performed at the clinical lab of the Cyprus Institute of 
Neurology and Genetics under standard hospital procedures 
 
Statistical Analysis 
The normality of data was assessed by the Kolmogorov–Smirnov test. Unpaired t-
tests were used to compare the two groups for continuous normally distributed 
10 
 
variables, Mann-Whitney U test was used for non-normally distributed variables, 
whilst chi-square test was used for categorical variables. The Pearson correlation test 
was used to assess the relationship between the severity of RLS symptoms (quantified 
by the IRLS score) and the examined variables. Finally, multiple linear regression 
analysis was used to determine the factors associated with HRQoL. All analyses were 
carried out using the Statistical Package for the Social Sciences software (SPSS for 
Windows, version 19.0, Chicago, Illinois). Data are presented as mean ± SD (95% 
Confidence Intervals) and the level for statistical significance was set at P≤0.05.  
 
Results 
The prevalence of RLS among this sample of relapsing-remitting MS patients was 
20%. The patients’ characteristics divided into two groups according to RLS 
diagnosis are presented in Table 1. None patient experienced RLS symptoms before 
the onset of Multiple Sclerosis. Iron values were lower in the RLS group compared to 
the MS-RLS- group (p= 0.009). In contrast, ferritin levels did not differ between the 
two groups (p= 0.870). 
The patients of the RLS group were found to have significantly worse score in the 
mental component of the SF-36 questionnaire, in the PSQI and BDI (p < 0.05) (Table 
2).  
The patients’ data regarding functional capacity and body composition are presented 
in Table 3. Performance in the sit to stand tests was worse in the MS-RLS+ group (p 
<0.05) whereas significantly higher values were observed in the same group in 
regards to total body fat, trunk fat and abdominal girth (p <0.05). 
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Moreover, within the MS-RLS+ group, IRLS score was positively associated with 
BMI (r = 0.295, p= 0.038), PSQI (r= 0.501, p= 0.000), BDI (r= 0.477, p= 0.000), 
EDSS score (r= 0.349, p= 0.013), STS-5 (r= 0.395, p= 0.005), total body fat (r= 
0.390, p= 0.005), trunk fat (r= 0.361, p= 0.010) and fatigue index (r= 0.537, p= 
0.000). Negative correlations were observed between the IRLS score and iron levels 
(r= -0. 408, p= 0.04),  the physical (r= -0. 370, p= 0.008) and mental (r= -0.327, p= 
0.021) component scores and the total score (r= -0.347, p= 0.014) of the SF-36 
questionnaire, STS-30 (r= -0.344, p= 0.014) and STS-60 (r= -0.442, p= 0.001). 
 
IRLS score, STS-5 and TUG as indices of functional capacity,  PSQI, BDI, fatigue 
index and iron levels  were included as independent variables in the linear multiple 
regression analysis to identify the factors associated with the total score of the SF-36 
questionnaire. Iron levels were found to be inversely associated with SF-36 total score 
(r
2
= -0.446, p= 0.004) whilst a trend towards significance was found in regards to 
IRLS score (r
2
= -0.320, p= 0.071) and fatigue index (r
2
= -0.387, p= 0.062) (Table 4).  
 
 
Discussion 
In the current study we firstly present data regarding functional capacity levels of MS 
patients with and without RLS and data regarding RLS in MS patients in the Cyprus 
area. We observed that the MS patients with RLS experience even further 
impairments in depression symptoms, sleep quality, functional capacity and therefore 
greater fatigue and lower health-related quality of life levels compared to MS patients 
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without RLS. Moreover, the patients with RLS were found to have significantly 
higher total and trunk fat levels.  
 
Sleep disorders reported to be highly prevalent in the MS population. A recent meta-
analysis and systematic review article report that the prevalence of RLS in the MS 
population varies between 13.3% to 65.1%, partially depending on the method of 
assessment [6]. By using a face to face interview, the prevalence of RLS in our MS 
population was 20%. Idiopathic etiology RLS has been excluded since none of the 
patient experienced RLS symptoms before the onset of Multiple Sclerosis. 
 
Fatigue is considered to be one of the main problem that the MS patients facing, 
affecting their quality of life and general wellbeing. Fatigue has been proposed to be 
multifactorial in the MS population [20]. In the last years, there are a growing number 
of published studies regarding the association between sleep disorders such as RLS 
and fatigue in MS patients. Sleep is well established as a key-factor for fatigue and 
tiredness in the MS population [20]. We observed that the patients with RLS 
experience significantly poorer sleep quality compared to the patients without RLS, 
confirming previous studies [9]. We should note that according to the PSQI observed 
in this study, the patients with RLS can be classified as patients with poor sleep 
quality. In the current study, fatigue index score in the MS-RLS+ patient is above the 
cut-off points of fatigue and was found to be significantly higher in the MS-RLS+ 
group, whilst a strong correlation was found between the severity of RLS symptoms 
and fatigue index. Those data are in line with previous studies in which RLS presence 
was associated with greater fatigue in MS patients [6, 9, 21]. The greater levels of 
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fatigue of the MS patients with RLS can be partially explained by the negative effects 
of the syndrome on sleep, functional capacity and depression levels revealed by the 
outcomes of the current study, confirming previous findings [20]. 
 
Multiple Sclerosis is a neurological disease which is associated with long-term 
physical and functional disability. Levels of disability were found to be significantly 
higher in the patients with RLS compared with the patients without RLS, whilst the 
RLS severity was positively associated with the EDSS score confirming previous data 
[22]. Until now, no other evidence exists regarding the potential effect of RLS on 
functional capacity levels in MS patients. Our findings suggest a negative effect of the 
syndrome on functional capacity as expressed by the patient’s performance in a 
battery of functional tests. A closer view to the functional capacity data reveal that the 
patients with RLS performed worse only in the functional tests in which lower 
extremities strength and power are considered to be the key factor performance 
parameters such as the “sit to stand” tests. Data derived by patients with uremic RLS 
revealed increased muscle atrophy in the thigh muscles [23], whilst muscle biopsies 
from idiopathic RLS patients reveal significant capillary remodelling in the 
morphology of the tibialis anterior muscle of idiopathic RLS patients [24]. Indeed in 
the later study, aerobic performance as assessed by a cycle ergometer test was found 
to be significantly decreased in the RLS patients compared to age-matched 
individuals without RLS. In addition, the greater fatigue and the poorer sleep quality 
of the MS-RLS+ patients may explain the differences between the two groups in 
regards to functional capacity.  
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It is well known that HRQoL is impaired in the Multiple Sclerosis patients. Various 
factors have been reported to be associated with the impaired HRQoL of the MS 
population including fatigue and depression, sleep and physical disability [8]. 
Surprising, and as stated also in a recent systematic review [6], no cross-sectional 
studies are available in regards to examining potential differences in HRQoL between 
MS patients with and without RLS. According to our data, the patients of the RLS 
group were found to experience further impairments on various factors which are 
known to be associated with HRQoL in the MS population such as sleep, depression, 
functional capacity, confirming previous findings [9]. We should note that the score 
observed in the current study in regards to the BDI questionnaire of the MS-RLS+ 
patients indicated patients with mild depression. Daily sleepiness status did not found 
to differ between the patients with and without RLS, in contrast to other studies [21], 
however supporting other studies in RLS patients [23]. Finally, the multiple linear 
regression analysis performed in the current study revealed that RLS severity, sleep 
quality and fatigue levels were independently associated with HRQoL in this sample 
of relapsing-remitting MS patients.  
 
According to our knowledge, these are the first data regarding body composition (i.e. 
body fat) in MS patients with and without RLS. Interestingly, we found that the MS-
RLS+ group exhibited a greater level of both total body fat and trunk fat compared to 
patients without RLS. In addition, a trend towards significance was found in regards 
to BMI, which appear higher in the MS-RLS+ group. Published evidence exists 
regarding possible associations between RLS and obesity indices such as BMI in MS 
[25] and non-MS populations [26, 27], however, other studies did not confirm such an 
association [23]. The high fat levels of the RLS patients may explained by several 
15 
 
factors associated with RLS, including nocturnal eating [28], sleep loss and sleep 
deprivation-related metabolic and hormonal abnormalities [29]. In addition, as 
reported above, the patients with RLS were found to experience high fatigue levels. It 
is possible that fatigue acted as a barrier to exercise and physical activity leading to 
inactivity and fat gain. Moreover, RLS in MS patients is more frequent in subjects 
with frequent in subjects with spinal lesion which could reduce mobility [30]. We 
should note that MS patients having such high total body fat and trunk fat levels are 
considered to be at high risk for developing cardiovascular diseases and metabolic 
syndrome [31]. More research is needed in order to clarify the association between fat 
levels and RLS in the MS population.  
 
Low iron levels have been associated with both presence and severity of RLS in 
idiopathic patients [32]. We found that iron levels were significantly lower in the RLS 
group compared to the non-RLS group, confirming previous studies[6]. Moreover, 
according to the data of the current study, the severity of RLS correlated with iron 
levels. However, we should note that other studies did not confirm any association 
between iron levels and RLS presence and severity in MS patients [4]. On the other 
hand, ferritin levels did not differ between the two groups. Taking into account the 
controversy in regards to the relationship between RLS and iron in MS patients and 
the fact that ferritin levels in the current study did not differ between the two groups 
we assume that this form of RLS associated with MS may doesn’t depend on iron but 
on other MS-related pathophysiological characteristics such as Central Nervous 
System lesions (i.e. a real secondary RLS form).  
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According to the literature, interventions resulted to the management of the RLS 
symptoms could result among others in enhancements of quality of life, depression 
and overall health parameters [2]. Taking into account the high prevalence of RLS in 
the MS patients and the negative effect of the syndrome on various aspects of quality 
of life, health and wellbeing, early diagnosis and successful management of RLS 
should be targets of the neurologists and MS care providers.  
 
Unfortunately, in the current study we did not assess factors which are associated to 
the development of chronic diseases such as cardiovascular diseases, diabetes, 
hypertension and hypercholesterolemia. Therefore we lost the opportunity to examine 
whether the MS patients with RLS may experience increased risk for developing 
those diseases. Moreover, we should note that only patients with Relapsing-Remitting 
MS participated in the current study. Is still not clear whether the clinical subtype of 
MS is affecting the presence of RLS in the MS population. Published data reveal that 
primary progressive MS patients may exhibit an increased risk for RLS compared to 
the other MS subtypes [4, 22]. On the other hand, other studies observed higher 
prevalence of RLS in Relapsing-Remitting MS [33] and in secondary progressive MS 
[34]. 
 
In conclusion, the findings of the current study indicate the negative impact of RLS 
on sleep quality, depression, fatigue, health-related quality of life and functional 
capacity of MS patients whilst an association between RLS and cardiovascular 
disease risk factors such as high total body and trunk fat levels is uncovered as well. 
On the other hand, undertreatment of RLS in MS population is very common. Future 
prospective interventional studies are warrant to understand whether RLS treatment in 
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these patients will improve fatigue, overall health and quality of life of the MS 
patients who suffer also from RLS as well as to verify if losing weight and body fat 
might be a therapeutical option to reduce the severity of RLS symptoms and therefore 
reduce fatigue and improve health-related quality of life.  
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Tables and Figures 
Table 1- Patient’s characteristics divided in two groups according to RLS diagnosis. 
Variables MS-RLS+ MS-RLS- p value 
N 10 40 - 
Female / Male 7/3 17/23 0.470
a
 
Age (yr) 39.9±9.2 38.1±6.5 0.481 
Weight (kg) 79.0±13.3 69.7±15.9 0.095 
Height (cm) 167.3±9.9 165.6±7.2 0.547 
IRLS score 19.9±5.4 - - 
EDSS score 3.0±1.2 2.2±0.9 0.043 
Iron (μg/dL) 55.0±24.9 86.5±34.1 0.009 
Ferritin (ng/ml) 76.0±51.5 82.7±73.4 0.896
b
 
Hct 40.1±2.7 40.1±3.1 0.983 
Hb (g/dL) 13.2±1.4 13.3±1.3 0.830 
All data are mean  SD.  Abbreviations: IRLS, International Restless Legs Syndrome 
severity scale; EDSS, expanded disability status scale score, Hct, haematocrit; Hb, 
haemoglobin.  
a
For categorical data a chi-square test was performed 
b
 For data without normal distribution a Mann-Whitney U test
 
was performed  
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Table 2- Health-related quality of life, depression, fatigue, daytime sleepiness and sleep quality 
data divided in two groups according to RLS diagnosis. 
Variables MS-RLS+ MS-RLS- p value 
SF-36 MCS 
95% CI 
58.5±21.7 
42.9 to 74.1 
75.0±19.6 
68.7 to 81.2 
0.011
b
 
SF-36 PCS 
95% CI 
61.2±22.2 
45.3 to 77.1 
73.3±17.2 
67.7 to 78.8 
0.083
b
 
SF-36 total score 
95% CI 
62.7±19.8 
48.5 to 76.8 
76.1±18.3 
70.2 to 81.9 
0.047 
Pittsburgh Sleep Quality Index 
95% CI 
7.0±5.6 
2.9 to 11.1 
2.9±2.4 
2.1 to 3.7 
0.004
b
 
Epworth Sleepiness Scale 
95% CI 
5.2±6.8 
0.2 to 10.1 
3.2±4.2 
1.8 to 4.5 
0.246 
Beck Depression Inventory 
95% CI 
16.5±17.2 
4.1 to 28.8 
4.2±6.4 
2.1 to 6.3 
0.005
b
 
Fatigue Severity Scale Index 
95% CI 
5.8±0.9 
5.1 to 6.5 
4.3±1.0 
4.0 to 4.7 
0.000 
All data are mean  SD (95% Confidence Intervals). SF-36, 36-Item Short Form Health 
Survey; MCS, mental component score; PCS, physical component score 
b
 For data without normal distribution a Mann-Whitney U test
 
was performed  
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Table 3- Functional capacity and body composition data divided in two groups according to RLS 
diagnosis. 
Variables MS-RLS+ MS-RLS- p value 
Functional capacity data 
 STS- 5 (sec)  
95% CI 
14.4±3.4 
11.9 to 16.8 
11.9±2.6 
11.0 to 12.7 
0.016 
 STS-30 (rep) 
95% CI 
10.9±2.2 
9.3 to 12.4 
12.8±2.4 
12.1 to 13.6 
0.028 
STS-60 (rep) 
95% CI 
20.6±4.6 
17.2 to 23.9 
25.9±4.8 
24.3 to 27.5 
0.003 
Six-minute walk test (m) 
95% CI 
415.8±121.5 
328.8 to 502.7 
443.4±97.1 
412.4 to 474.5 
0.447 
TUG test (sec) 
95% CI 
9.3±1.8 
8.0 to 10.6 
8.5±1.5 
8.0 to 9.1 
0.169 
Body composition data 
Total fat (%) 
95% CI 
34.4±9.2 
27.8 to 41.1 
28.1±7.4 
25.7 to 30.5 
0.026 
Abdominal Girth (cm) 
95% CI 
104.8±14.8 
94.1 to 115.4 
92.3±13.9 
87.8 to 96.8 
0.016 
Trunk fat (%) 
95% CI 
38.6±11.8 
30.2 to 47.1 
31.0±9.7 
27.9 to 34.1 
0.039 
Body Mass Index 
95% CI 
28.3±5.4 
24.3 to 32.2 
25.2±5.0 
23.6 to 26.8 
0.097 
All data are mean  SD (95% Confidence Intervals). P values are adjusted for yrs in 
dialysis. Abbreviations: STS-5, sit-to- stand test 5-repetitions; STS-60, sit-to- stand test 
60 seconds; TUG, timed up and go test 
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Table 4: Multiple linear regression to evaluate the predictors of health-related quality 
of life (r
2
 = 0.386) 
Variable Coefficient Standard Error p value 
IRLS score -0.320 0.395 0.071 
STS-5 -0.052 1.199 0.781 
TUG -0.152 2.008 0.365 
PSQI score 0.083 0.795 0.588 
EDSS 0.202 2.921 0.210 
FSS index score -0.387 3.140 0.062 
BDI score -0.151 0.312 0.382 
Iron -0.446 0.083 0.004 
Abbreviations: IRLS, International Restless Legs Syndrome severity score; STS-5, 
sit-to- stand test 5-repetitions; TUG, timed up and go test; PSQI, Pittsburg Sleep 
Quality Index; EDSS, expanded disability status scale; FSS, fatigue severity scale 
BDI, Beck Depression Inventory 
 
